Near future of tumor immunology: Anticipating resistance mechanisms to immunotherapies, a big challenge for clinical trials

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCATANI, Joao Paulo Portela
dc.contributor.authorRIECHELMANN, Rachel P.
dc.contributor.authorADJEMIAN, Sandy
dc.contributor.authorSTRAUSS, Bryan E.
dc.date.accessioned2017-08-17T19:21:07Z
dc.date.available2017-08-17T19:21:07Z
dc.date.issued2017
dc.description.abstractThe success of immunotherapies brings hope for the future of cancer treatment. Even so, we are faced with a new challenge, that of understanding which patients will respond initially and, possibly, develop resistance. The examination of the immune profile, especially approaches related to the immunoscore, may foretell which tumors will have a positive initial response. Ideally, the mutation load would also be analyzed, helping to reveal tumor associated antigens that are predictive of an effective cytolytic attack. However, the response may be hindered by changes induced in the tumor and its microenvironment during treatment, perhaps stemming from the therapy itself. To monitor such alterations, we suggest that minimally invasive approaches should be explored, such as the analysis of circulating tumor DNA. When testing new drugs, the data collected from each patient would initially represent an N of 1 clinical trial that could then be deposited in large databases and mined retrospectively for trends and correlations between genetic alterations and response to therapy. We expect that the investment in personalized approaches that couple molecular analysis during clinical trials will yield critical data that, in the future, may be used to predict the outcome of novel immunotherapies.
dc.description.indexMEDLINE
dc.description.sponsorshipSao Paulo Research Foundation [13/25167-5, 14/11524-3, 12/25380-8]
dc.identifier.citationHUMAN VACCINES & IMMUNOTHERAPEUTICS, v.13, n.5, p.1109-1111, 2017
dc.identifier.doi10.1080/21645515.2016.1269046
dc.identifier.eissn2164-554X
dc.identifier.issn2164-5515
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/21467
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS INC
dc.relation.ispartofHuman Vaccines & Immunotherapeutics
dc.rightsrestrictedAccess
dc.rights.holderCopyright TAYLOR & FRANCIS INC
dc.subjectcancer
dc.subjectcheckpoint blockade
dc.subjectcirculating tumor DNA
dc.subjectimmunoscore
dc.subjectpersonalized medicine
dc.subject.othermelanoma
dc.subject.otherblockade
dc.subject.othercancer
dc.subject.wosBiotechnology & Applied Microbiology
dc.subject.wosImmunology
dc.titleNear future of tumor immunology: Anticipating resistance mechanisms to immunotherapies, a big challenge for clinical trials
dc.typearticle
dc.type.categoryeditorial material
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalADJEMIAN, Sandy:Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Lab Cell & Mol Biol, Sao Paulo, Brazil
hcfmusp.citation.scopus7
hcfmusp.contributor.author-fmusphcJOAO PAULO PORTELA CATANI
hcfmusp.contributor.author-fmusphcRACHEL SIMOES PIMENTA RIECHELMANN
hcfmusp.contributor.author-fmusphcBRYAN ERIC STRAUSS
hcfmusp.description.beginpage1109
hcfmusp.description.endpage1111
hcfmusp.description.issue5
hcfmusp.description.volume13
hcfmusp.origemWOS
hcfmusp.origem.pubmed28059608
hcfmusp.origem.scopus2-s2.0-85019621280
hcfmusp.origem.wosWOS:000401516100029
hcfmusp.publisher.cityPHILADELPHIA
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAsghar W, 2016, SCI REP-UK, V6, DOI 10.1038/srep21163
hcfmusp.relation.referenceBendell J, 2016, J CLIN ONCOL, V34, P1764
hcfmusp.relation.referenceCatenacci DVT, 2015, MOL ONCOL, V9, P967, DOI 10.1016/j.molonc.2014.09.011
hcfmusp.relation.referenceChang-Hao Tsao S, 2015, SCI REP, V5, P11198, DOI 10.1038/SREP11198
hcfmusp.relation.referenceGalon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
hcfmusp.relation.referenceGuinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
hcfmusp.relation.referenceHolzel M, 2016, TRENDS IMMUNOL, V37, P364, DOI 10.1016/j.it.2016.03.009
hcfmusp.relation.referenceJuergens Rosalyn A, 2016, Biomark Cancer, V8, P1, DOI 10.4137/BIC.S31805
hcfmusp.relation.referenceKirilovsky A, 2016, INT IMMUNOL, V28, P373, DOI 10.1093/intimm/dxw021
hcfmusp.relation.referenceLe DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJM0A1500596
hcfmusp.relation.referencePitt JM, 2016, IMMUNITY, V44, P1255, DOI 10.1016/j.immuni.2016.06.001
hcfmusp.relation.referenceCatani JPP, 2016, TRANSL ONCOL, V9, P565, DOI 10.1016/j.tranon.2016.09.011
hcfmusp.relation.referenceShankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122
hcfmusp.relation.referenceSnyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498
hcfmusp.relation.referenceTan ACL, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0093-x
hcfmusp.relation.referenceVANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703
hcfmusp.relation.referenceXi LQ, 2016, CLIN CANCER RES, V22, P5480, DOI 10.1158/1078-0432.CCR-16-0613
hcfmusp.relation.referenceZaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958
hcfmusp.scopus.lastupdate2024-06-09
relation.isAuthorOfPublicationed73ed56-9d6b-4eaf-8cb9-e9c534d692c7
relation.isAuthorOfPublication7791870c-e5e2-4215-8209-16f0401d6ffe
relation.isAuthorOfPublication2dcf8225-1aa3-4b94-869a-6769561b3515
relation.isAuthorOfPublication.latestForDiscoveryed73ed56-9d6b-4eaf-8cb9-e9c534d692c7
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_CATANI_Near_future_of_tumor_immunology_Anticipating_resistance_mechanisms_2017.PDF
Tamanho:
1008.34 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03